Tandem Diabetes Care (TNDM) had the highest return in 2018 by a mid-cap US stock, returning 1,515.7%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Tandem Diabetes Care (TNDM) | 2018 | 1,515.74% |
Arrowhead Pharmaceuticals (ARWR) | 2018 | 236.59% |
Vericel Corp Ord (VCEL) | 2018 | 213.51% |
PAR Technology (PAR) | 2018 | 132.62% |
Etsy (ETSY) | 2018 | 132.05% |
Xenon Pharmaceuticals (XENE) | 2018 | 125.36% |
Amedisys (AMED) | 2018 | 121.38% |
Goosehead Insurance (GSHD) | 2018 | 119.08% |
Glaukos (GKOS) | 2018 | 116.87% |
Energy of Minas Gerais Co DRC (CIG.C) | 2018 | 113.92% |
Evertec (EVTC) | 2018 | 109.55% |
Krystal Biotech (KRYS) | 2018 | 107.8% |
Crocs (CROX) | 2018 | 105.54% |
CleanSpark (CLSK) | 2018 | 105% |
PTC Therapeutics (PTCT) | 2018 | 103.56% |
Magnite (MGNI) | 2018 | 99.47% |
Enphase Energy (ENPH) | 2018 | 97.91% |
Companhia Energetica de Minas Gerais CEMIG Pref ADR (CIG) | 2018 | 95.42% |
Addus HomeCare (ADUS) | 2018 | 94.5% |
Veracyte (VCYT) | 2018 | 92.06% |
Viking Therapeutics (VKTX) | 2018 | 87.04% |
Sunrun (RUN) | 2018 | 85.2% |
Wingstop (WING) | 2018 | 84.9% |
Applied Digital (APLD) | 2018 | 83.33% |
R1 RCM (RCM) | 2018 | 79.86% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
